摘要
<正>血管免疫母细胞T细胞淋巴瘤(angioimmunoblastic T cell lymphoma,AITL)是外周T细胞淋巴瘤的特殊类型,仅占非霍奇金淋巴瘤的1%～2%,占所有外周T细胞淋巴瘤的15%～20%。AITL早期临床表现不典型,中晚期多以广泛的淋巴结受累、结外疾病、免疫性溶血及多克隆的高丙种球蛋白血症为特点[1]。AITL的侵袭性高,起病
Angioimmunoblastic T cell lymphoma(AITL)is special type of peripheral T cell lymphoma,accounting for only 1%to 2% of non Hodgkin lymphoma and accounting for 15% to 20% of all peripheral T cell lymphomas.The early clinical manifestation of AITL is not typical,and most of middle and advanced stage is characterized by extensive lymph node involvement,extranodal disease,immunological hemolysis and polyclonal gamma globulin.AITL has high invasiveness,rapid onset and poor prognosis,the 5 year survival rate is about 30%.At present,there is no effective first-line treatment for AITL,the treatment regimen is based on CHOP combined with autologous hematopoietic stem cell transplantation,and complete remission rate is 39% to 50%,which has some limitations.Recently we found the treatment of chidamide combined with DICE effective in a case of recurrent/refractory AITL combined with autoimmune hemolytic anemia,and the report is as follow.
引文
[1]罗会芹.血管免疫母细胞性T细胞淋巴瘤的治疗进展[J].肿瘤预防与治疗,2013,26(6):355-360.
[2]De LL,Gisselbrecht C,Gaulard P.Advances in the understanding and management of angioimmunoblastic T-cell lymphoma[J].Br J Haematol,2010,148:673-689.
[3]沈建箴.血管免疫母T细胞淋巴瘤诊治的进展[J].临床血液学杂志,2016,29(9):708-710.
[4]Julie V,James A,Dennis W.International peripheral T-cell and natural killer/T-cell lymphoma study:pathology findings and clinical outcomes[J].J Clin Oncol,2008,26:4124-4130.
[5]Abouyabis AN,Shenoy PJ,Lechowicz MJ,et al.Incidence and outcomes of the peripheral T-cell lymphoma subtypes in the United States[J].Leuk Lymphoma,2009,49:2099-2107.
[6]蔡真.T及NK细胞淋巴瘤诊治进展[J].临床血液学杂志,2016,29(9):703-707.
[7]Chan TS,Tse E,Kwong YL.Chidamide in the treatment of peripheral T-cell lymphoma[J].Onco Targets Ther,2017,10:347-352.
[8]Dayan K,Keser A,Konyalioglu S,et al.The effect of hyperbaric oxygen on neuroregeneration following acute thoracic spinal cord injury[J].Life Sci,2012,90:360-364.
[9]沈志祥.西达本胺治疗外周T细胞淋巴瘤中国专家共识(2016版)解读[J].中国肿瘤临床,2016,43(13):317-323.
[10]Shi Y,Bo J,Wei X,et al.Chidamide in relapsed or refractory peripheral T cell lymphoma:a multicenter real-world study in China[J].J Hematol Oncol,2017,10:69.
[11]Lin SH,Wang BY,Lin CH,et al.Chidamide alleviates TGF-β-induced epithelial-mesenchymal transition in lung cancer cell lines[J].Mol Biol Rep,2016,43:687-695.
[12]He M,Qiao Z,Wang Y,et al.Chidamide inhibits aerobic metabolism to induce pancreatic cancer cell growth arrest by promoting Mcl-1degradation[J].PLos One,2016,11:e0166896.
[13]Wang H,Guo Y,Fu M,et al.Antitumor activity of Chidamide in hepatocellular carcinoma cell lines[J].Mol Med Rep,2012,5:1503-1508.
